Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Soonmo Peter Kang

Showing results (11-20 of 13) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 13 results.
The International Journal of Biological Markers|May 1, 2009
Circulating tumor cells in HER-2 positive metastatic breast cancer patients treated with trastuzumab and chemotherapyRaquel A Nunes, Xiaochun Li, Soonmo Peter Kang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 22, 2015
Phase I dose-escalation trial of checkpoint kinase 1 inhibitor MK-8776 as monotherapy and in combination with gemcitabine in patients with advanced solid tumorsAdil I Daud, Michelle T Ashworth, Jonathan Strosberg, et al.
Molecular Cancer Therapeutics|April 2, 2020
Biophysical and Immunological Characterization and <i>In Vivo</i> Pharmacokinetics and Toxicology in Nonhuman Primates of the Anti-PD-1 Antibody PembrolizumabBeth Hutchins, Gary C Starling, Mark A McCoy, et al.
Pageof 2

Showing results (11-20 of 13) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 13 results.
The International Journal of Biological Markers|May 1, 2009
Circulating tumor cells in HER-2 positive metastatic breast cancer patients treated with trastuzumab and chemotherapyRaquel A Nunes, Xiaochun Li, Soonmo Peter Kang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 22, 2015
Phase I dose-escalation trial of checkpoint kinase 1 inhibitor MK-8776 as monotherapy and in combination with gemcitabine in patients with advanced solid tumorsAdil I Daud, Michelle T Ashworth, Jonathan Strosberg, et al.
Molecular Cancer Therapeutics|April 2, 2020
Biophysical and Immunological Characterization and <i>In Vivo</i> Pharmacokinetics and Toxicology in Nonhuman Primates of the Anti-PD-1 Antibody PembrolizumabBeth Hutchins, Gary C Starling, Mark A McCoy, et al.
Pageof 2